Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: J Clin Lipidol. 2009;3(3):167–178. doi: 10.1016/j.jacl.2009.04.052

Figure 3.

Figure 3

Percentage changes in lipoprotein levels from baseline on monotherapy (Week 12) and combined Therapy (Week 24). Primary end points are % change in LDL-C in single and combined drug treatment. ●--● Atorvastatin + Slo-niacin; ○- -○ Slo-Niacin + Atorvastatin *p<0.05, **p<0.01,***p<0.001